性腺刺激ホルモン放出ホルモンアナログ化合物 gonadotropin-releasing hormone analog
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 生殖腺毒性を有する治療または生殖腺切除術を施行した患者における不妊の予防 fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection
- 2. 非転移性ホルモン受容体陽性乳癌に対する補助内分泌療法 adjuvant endocrine therapy for non metastatic hormone receptor positive breast cancer
- 3. 思春期早発症の治療 treatment of precocious puberty
- 4. 男性における乳癌 breast cancer in men
- 5. 妊娠月齢に比して小さい小児に対する成長ホルモン治療 growth hormone treatment for children born small for gestational age
English Journal
- Treated and untreated women with idiopathic precocious puberty: long-term follow-up and reproductive outcome between the third and fifth decades.
- Lazar L1, Meyerovitch J, de Vries L, Phillip M, Lebenthal Y.Author information 1The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.AbstractCONTEXT: Central precocious puberty (CPP), treated or untreated, may have implications in adulthood.
- Clinical endocrinology.Clin Endocrinol (Oxf).2014 Apr;80(4):570-6. doi: 10.1111/cen.12319. Epub 2013 Sep 18.
- CONTEXT: Central precocious puberty (CPP), treated or untreated, may have implications in adulthood.OBJECTIVE: To assess the reproductive outcome and social adjustment of former CPP women between the 3rd and 5th decades of life.DESIGN: Cross-sectional study of an historical cohort.METHODS: Demograph
- PMID 24033561
- Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma.
- Marshall DT1, Ramey S2, Golshayan AR2, E Keane T2, Kraft AS2, Chaudhary U3.Author information 1Medical University of South Carolina, Charleston, SC. Electronic address: marshadt@musc.edu.2Medical University of South Carolina, Charleston, SC.3University of California, San Francisco, Fresno, CA.AbstractBACKGROUND: This was a phase I study to find the maximum tolerable dose (MTD) of weekly docetaxel combined with high-dose intensity-modulated radiotherapy (IMRT) and androgen deprivation therapy (ADT).
- Clinical genitourinary cancer.Clin Genitourin Cancer.2014 Apr;12(2):80-6. doi: 10.1016/j.clgc.2013.11.019. Epub 2013 Nov 13.
- BACKGROUND: This was a phase I study to find the maximum tolerable dose (MTD) of weekly docetaxel combined with high-dose intensity-modulated radiotherapy (IMRT) and androgen deprivation therapy (ADT).PATIENTS AND METHODS: Men with localized high-risk prostate cancer (HRPC) were treated with weekly
- PMID 24378335
- Protection of ovarian function by GnRH agonists during chemotherapy: A meta-analysis.
- Sun X, Dongol S, Jiang J, Kong B.Author information Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan 250012, P.R. China.AbstractThis meta-analysis was designed to assess the overall performance of GnRHa in preserving the ovarian function in young women undergoing chemotherapy. Electronic literature databases including Pubmed, MEDLINE, Cochrane library, Embase, CNKI and Wanfang were searched for articles published till November, 2013. The articles written in both Chinese and English were considered. Only randomized controlled trials (RCTs) were selected. Main Outcome Measure was evaluated by assessing the post‑chemotherapy ovarian function. A random-effects model was used to calculate the risk ratio (RR) and associated 95% confidence intervals (95% CI). Out of the eight RCTs including 621 patients, 321 women were treated with GnRHa during chemotherapy, 9.66% of whom suffered premature ovarian failure (POF). On the other hand, 26.67% of the remaining 300 women suffered POF. More women treated without GnRHa experienced post-chemotherapy POF, yielding an RR of 0.45 [chemotherapy plus GnRHa vs. chemotherapy alone, 95% confidence interval (CI) (0.22, 0.92)]. Based on the available studies, GnRHa plays an important role in the prevention of post-chemotherapy POF, but does not exhibit its protective effects in fertility.
- International journal of oncology.Int J Oncol.2014 Apr;44(4):1335-40. doi: 10.3892/ijo.2014.2296. Epub 2014 Feb 11.
- This meta-analysis was designed to assess the overall performance of GnRHa in preserving the ovarian function in young women undergoing chemotherapy. Electronic literature databases including Pubmed, MEDLINE, Cochrane library, Embase, CNKI and Wanfang were searched for articles published till Novemb
- PMID 24535045
Japanese Journal
- Involvement of hormones in olfactory imprinting and homing in chum salmon
- Scientific reports 6, 21102, 2016-02-17
- NAID 120005743060
- Decreased expression of human heat shock protein 70 in the endometria and pathological lesions of women with adenomyosis and uterine myoma after GnRH agonist therapy
- European Journal of Obstetrics & Gynecology and Reproductive Biology 187, 6-13, 2015-04
- NAID 120005553903
- P3-29-2 子宮内膜症に対するGnRHa療法が子宮腔内の細菌コンタミネーションおよび子宮内膜炎に及ぼす影響に関する検討(Group131 子宮内膜症3 卵巣予備能,一般演題,公益社団法人日本産科婦人科学会第67回学術講演会)
- 日本産科婦人科學會雜誌 67(2), 890, 2015-02-01
- NAID 110009941744
Related Links
- GnRHa療法 「GnRHa」は（gonadotropin releasing hormone analog）の略で、GnRHa療法とはこれを少量または持続的に投与することによってゴナドトロピンの分泌を促す治療法だ。 不妊治療成功者の症例
- 順天堂大学医学部附属順天堂医院産婦人科 GnRH アゴニストを投与される患者さまへ 1. GnRH アゴニストとは、脳下垂体に働いて卵巣を刺激するホルモンの分泌を下げ て卵巣の働きを抑えるお薬です。GnRH アゴニストはアミノ酸が9～10 個結合した
- グ（GnRHa）が魚類の人為催熟および産卵誘発に広く 利用されている。6,8,9)GnRHaの投与は，注射による投 与に比べて長期間ホルモンを作用させることが可能であ る徐放性ペレットを，腹腔内または筋肉中に埋め込むイ
Related Pictures
★リンクテーブル★
| リンク元 | 「性腺刺激ホルモン放出ホルモンアナログ化合物」「gonadotropin-releasing hormone analog」 |
| 関連記事 | 「GnRH」 |
「性腺刺激ホルモン放出ホルモンアナログ化合物」
- 英
- gonadotropin-releasing hormone analog GnRHa
- 同
- GnRHアナログ GnRH analog
- 関
- 性腺刺激ホルモン放出ホルモン誘導体、性腺刺激ホルモン放出ホルモン拮抗物
「gonadotropin-releasing hormone analog」
[★] 性腺刺激ホルモン放出ホルモンアナログ化合物, GnRHa